Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F01 in Moderate-to-severe Refractory SLE
NCT06468683Phase 1Not yet recruiting
- Sponsor
- Simnova Biotherapeutics
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC103 in systemic lupus erythematosus (SLE), sponsored by Simnova Biotherapeutics. Primary endpoint: Incidence of Adverse Events and Dose-Limiting Toxicities at 12 weeks. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
SNC103
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06468683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468683.